AI(d) To Increase Drug Discovery Productivity And Optimize SPR Data Interpretation
By Paul Belcher, Product Strategy Manager, and Martin Teichert, Global Product Manager, Cytiva
Due to the high attrition rates in drug development, there is increasing pressure in the pharmaceutical industry, yet the efficiency of research and development has not increased. Developers have more samples to test and more information to collect, with less time to make decisions.
Therefore, there’s demand for information-rich technologies that can be applied earlier in the drug discovery process. While some of the current data analysis tools have improved, developers are still faced with time-consuming, manual approaches.
Explore a machine learning solution to optimize how developers analyze and characterize their early drug candidates.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.